Efficacy of Adjunctive Low-Level Light Therapy to Intense Pulsed Light for Meibomian Gland Dysfunction

Launched by CHULALONGKORN UNIVERSITY · Jun 16, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring whether adding low-level light therapy (LLLT) to intense pulsed light (IPL) treatments can improve care for people suffering from meibomian gland dysfunction (MGD). MGD is a condition that can cause dry eyes and discomfort due to problems with the glands that produce oils in the eyelids. The study will compare two groups: one receiving just IPL treatment and the other receiving both IPL and LLLT, to see if the combination works better.

To participate in this trial, you should be between 65 and 74 years old and have a moderate to severe level of MGD. However, certain individuals will not be eligible, such as those who have had eye surgery recently, wear contact lenses, or have other specific medical conditions. Participants will receive either the combined treatment or IPL alone and will be monitored for improvements in their eye health. If you meet the criteria and are interested, this trial could help find better treatment options for MGD.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • MGD severity level 2 and above according to the international workshop on MGD
• • Fitzpatrick skin type of 1-4 according to sun sensitivity characteristics and appearance of the skin color
• Exclusion Criteria:
• • History of previous ocular trauma or surgery within the past six months
• • Contact lens-wearing patients
• • Patients with skin-pigmented lesions in the treatment area
• • Pregnancy or breastfeeding patients
• • Patients with any uncontrolled ocular or systemic diseases